Brukinsa (zanubrutinib)
pCPA File Number:
21965
Negotiation Status:
Negotiations were not pursued
Indication(s):
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
Sponsor/Manufacturer:
BeiGene, Ltd.
CDA-AMC Project Number:
PC0267-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: